Are you lifting heavier weights or completing more reps
In contrast, treatment with the GLP-1 receptor agonist liraglutide yielded a small improvement in kidney function at the end of the follow-up period [89], and in two large-scale trials, the use of SGLT2 inhibitors was accompanied by a meaningful and durable improvement in glomerular function and a reduction in the risk of serious adverse renal events [56, 58]
However, the results can vary from individual to individual based on several factors such as the bodys response to the treatment, the persons overall health, and the duration of treatment
See more about the quarter's highlights, including our full-year guidance raise here Eli Lilly and Company Q1 2026: Momentum continues and guidance moves up Eli Lilly has started 2026 with another standout quarter, reinforcing just how much the GLP-1 wave is reshaping the pharma landscape
Electrolyte drinks can be considered if you sweat heavily
The additional glucagon receptor engagement in retatrutide produces distinct metabolic effects studied in research models
